Please login to the form below

Not currently logged in
Email:
Password:

Astellas signs CNS deal with BioFocus

Astellas Pharma is to focus on central nervous system (CNS) disorders with the help of BioFocus

Astellas Pharma has signed a collaboration agreement with BioFocus focused on discovering novel targets in the field of central nervous system disorders.  

Under the agreement, BioFocus will utilise its SilenceSelect target discovery platform to deliver validated targets to enhance the Astellas neurology pipeline and will receive research funding and success payments based on the progress of the collaboration.  

Dr Chris Newton, managing director of BioFocus, said: "We are delighted to support Astellas Pharma in its research. Our target discovery offering allows clients to access a unique platform providing rapid identification of novel targets through a proven technology."

12th May 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Kendle Healthcare

Company founder Neil Kendle was a pioneer in opinion leader engagement. In 2003, Neil brought together a small, dedicated team...

Latest intelligence

Report: Customer experience, shaping digital healthcare
In this issue of ‘Perspective’ we speak with industry experts to learn about the world of digital healthcare, and how pharma is beginning to utilise these modern technologies to enhance...
Biomarker
Encouraging signs in biomarker R&D
The cancer immunotherapy firms ramping-up biomarker R&D...
Programmatic methodology and why you should be using it
What is it? How does it work? Why is everyone talking about it? By Richard Webb - Associate Director...

Infographics